Maud Lemoine is a Consultant and Reader in Hepatology at St Mary’s hospital, Imperial College London, UK. She completed her medical degree and PhD in Paris, France. She also graduated in political sciences from the Institute of Political Studies in Paris. Her research activities are mainly focused on the prevention and management of viral hepatitis in resource-limited countries, mainly in Africa. Since 2011, she has been working with the Medical Research Council (MRC) The Gambia unit, as part of the hepatitis B PROLIFICA programme in The Gambia and Senegal. She is currently leading the PROLIFICA group.
Mark Thursz is Professor of Hepatology at Imperial College and Consultant in Hepatology at St Mary's Hospital, London. He is the previous chief investigator of PROLIFICA. He designed the first PROLIFICA studies on hepatitis B in West Africa with Dr Maimuna Mendy who were awarded funding from the European Commission to launch the programme. Prof. Thursz's clinical interests are in viral hepatitis, alcoholic liver disease and fatty liver disease.
Rita Carvalho is a project manager at Imperial College London. She completed her MSc in Biochemistry in Lisbon, Portugal, and her PhD in Biomedicine at the Faculty of Medicine, University of Utrecht, The Netherlands. She has been a Project Manager at Imperial College London since 2017, and has started project managing PROLIFICA in 2018.
Tim Hallett, based at the Department of Infectious Disease Epidemiology is Professor of Global Health. His work with the Applied HIV Epidemiology research group centres on the development and application of mathematical models for interpreting surveillence data, analyzing control trials and planning interventions. The overall aim of this research is to come to conclusions about the optimal use of limited resources in the response to HIV epidemic worldwide. He leads the HIV Modelling Consortium, which is a network epidemiologists, mathematical modellers and health-economists. He also works with UNAIDS and the Reference Group on Estimates, Modelling and Projections in developing the methods for calculating international AIDS statistics and serves on the PEPFAR Scientific Advisory Board.
Prof. Simon Taylor-Robinson (Imperial College London)
Simon Taylor-Robinson is Professor of Translational Medicine at Imperial College London and Consultant in Hepatology at St Mary's hospital. Over the past 30 years, he has investigated pathogenic mechanisms in chronic liver disease using a combination of imaging techniques, NMR spectroscopy and mass spectroscopy. Within the PROLIFICA study he supervised the work on HCC biomarkers.
Dr Shevanthi Nayagam (Imperial College London)
Shevanthi Nayagam is a Consultant in Hepatology and Senior lecturer at Imperial College London and has been mainly contributed to the modelling and economic evaluations related to PROLIFICA.
Dr Zameer Mohamed (Imperial College London), is a clinical research fellow at Imperial College London and a Specialist Registrar in Gastroenterology and Hepatology. He is completing his PhD, which is focused on improving access to HCV care in marginalised populations. He has received funding from the Wellcome Trust to evaluate screening and assessment of HCV among people who inject drugs. He has also developed the in-reach HCV prison service at HMP Wormwood Scrubs as part of the HCV West London Operational Delivery Network.
Graham Cooke is Professor of Infectious Diseases at Imperial College and NIHR Research Professor. His research has improved our understanding of the burden of viral hepatitis globally and defined the key steps necessary to achieve elimination (including leading the Commission on Accelerating the Elimination of viral hepatitis). As co-chair of the WHO Essential Medicines Committee he has led the adoption of new treatments for viral hepatitis and as chair of the BHIVA Expert group on hepatitis he has led development of national targets fro elimination of hepatitis C amongst those living with HIV. He leads strategic clinical trials of hepatitis C treatment in the UK and Asia and is active in developing and evaluating novel diagnostics through the NIHR MedTech In-vitro diagnostics co-operative.